HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

COVID-19 and cancer: How to protect ‘the most vulnerable’ during pandemic


When there are (almost) no data

John Sweetenham, MD

Meeting News

KTE-X19 induces durable responses in relapsed, refractory mantle cell lymphoma

Sitagliptin reduces acute GVHD after peripheral blood stem cell transplantation

Ado-trastuzumab emtansine extends DFS in early-stage HER2-positive breast cancer

Tailored rivaroxaban regimens safe, effective for children with venous thromboembolism

Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma

Novel small-molecule inhibitor ‘quite promising’ in advanced kidney cancer

Residual cancer burden predicts long-term outcomes across breast cancer subtypes

In the Journals

Early-onset gastric cancer, distinct from traditional disease, on the rise in US

Bleomycin regimen for germ cell cancer linked to increased cardiovascular risk

FDA News

FDA committee votes against approval of Tookad for localized prostate cancer

FDA approves neratinib regimen for HER2-positive metastatic breast cancer

FDA approves Sarclisa regimen for adults with advanced multiple myeloma

Jefferson's Kimmel Cancer Center names director of bone marrow transplant, immune cellular therapy

American Cancer Society names Medal of Honor recipients

Cedars-Sinai names lung cancer specialist head of medical oncology

Association names lectureship award after lung cancer specialist

Medical oncologist to receive award for cancer drug development